<DOC>
	<DOC>NCT01139203</DOC>
	<brief_summary>Entecavir demonstrated superior virologic and biochemical benefits over lamivudine and adefovir. The investigators evaluated the effect of entecavir combined Hepatitis B immune globulin (HBIG) with lamivudine or adefovir or both combined HBIG in Chinese liver transplantation patients with Hepatitis B Virus (HBV) related diseases.</brief_summary>
	<brief_title>Prophylaxis of Hepatitis B Virus Recurrence After Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1. patients into the transplant waiting list with HBVrelated liver disease. 2. HBsAgpositive. 3. serum HBVDNA negative. 4. no HCV, HDV and HIV coinfection. 5. without renal dysfunction. 6. No lamivudine, adefovir and entecavir drug allergy history. 7. no HBVYMDD mutation for patients who have a longterm use of lamivudine. 1. patients with HBVrelated hepatocellular carcinoma beyond Milan criteria. 2. HBsAgnegative. 3. serum HBVDNA positive. 4. HCV, HDV and HIV coinfection. 5. patients with severe renal dysfunction or failure. 6. lamivudine, adefovir and entecavir drug allergy history. 7. HBVYMDD mutation for patients who have a longterm use of lamivudine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>HBV recurrence</keyword>
	<keyword>entecavir</keyword>
</DOC>